What's a safe losartan dose for those without hypertension?

Tansia

Member
Joined
Jan 14, 2020
Messages
163
Hi All. I suffer from vulvodynia and Peat recommends angiotensin blockers for this condition. I haven't got hypertesnion, but I'm desperate to try that treatment. Have you experiemented with it for COVID or other issues and would like to share a dose or how you prevented hypotension from this drug? Thank you!
 

Elie

Member
Forum Supporter
Joined
Oct 30, 2015
Messages
818
Maybe start with a fraction of the starting dose for HBP (25 mg - 50 mg). so maybe 2.5 mg. Read all the potential side effect and pay close attention.
what caused the vulvodynia to begin with?
 
OP
T

Tansia

Member
Joined
Jan 14, 2020
Messages
163
Maybe start with a fraction of the starting dose for HBP (25 mg - 50 mg). so maybe 2.5 mg. Read all the potential side effect and pay close attention.
what caused the vulvodynia to begin with?
Vulvodynia was triggered by intravaginal herbal pressaries- it's been one year since it started and I'm really desperate to try anything that can help. Initially I thought that it's just irritation and tried but A and E and DHEA as at some point I thought this could be hormonal. But they didn't help.
 

Elie

Member
Forum Supporter
Joined
Oct 30, 2015
Messages
818
What about topical high dose progesterone?
 
OP
T

Tansia

Member
Joined
Jan 14, 2020
Messages
163
What about topical high dose progesterone?
@Elie you min dtopicl on vulva? I have not tried high doses as yet - only small doses.
I've tried all the recommendations form Ray (except ARBs) that I posted some time ago:
 

aliml

Member
Joined
Apr 17, 2017
Messages
692
Women with provoked vestibulodynia (PVD) compared to healthy controls (HC) had reduced concentrations of pregnenolone, progestin and androgen metabolites involved in the steroid hormone biosynthesis. These reductions were observed primarily in vaginal fluid not plasma suggesting localized effects in the vagina and vestibule rather than systemic alterations. The observed reductions in vaginal levels of several androgenic metabolites were associated with increased total vulvar vestibular pain and vaginal muscle tenderness and decreased functional connectivity in pain processing brain regions, the primary sensory and motor cortices. We observed that use of systemic hormonal contraceptives resulted reduced plasma concentrations of the metabolites involved in steroidogenesis in both PVD and HC. There was also some evidence that use of systemic hormones reduced vaginal levels of these metabolites in HCs but not PVD. Finally, pain duration, total vulvar vestibule pain and total vaginal muscle tenderness did not differ in women with PVD using systemic hormonal contraceptives compared to women not using hormones or those using local hormones.

The lower vaginal levels of steroidogenic metabolites in women with PVD, including androgenic steroids (e.g. 16a-hydroxy DHEA 3-sulfate and androstenediol disulfate, a metabolite of DHEA) and pregnenolone, a precursor to both progesterone and DHEA synthesis, could lead to alterations in mucosal structure and thinning of the mucosa of the vestibule rendering the tissue more vulnerable to injury and inflammation. The vaginal and vulvar epithelium express high levels of androgen receptors. Mucin-secreting vestibular glands also express high levels of androgen receptors; thus, changes in steroids observed in PVD group could ultimately contribute to decreased mucin production, vulnerability to chemical, physical or microbial damage and hypersensitivity. Androgens are aromatized to estrogens (not detected in the current dataset) therefore it is difficult to affirm that their final peripheral effect is caused by the androgens or by conversion to estrogens or by combination of both. Lower local concentrations of androgen could result in diminished estrogen binding in vulvar and vaginal tissues.

Because progesterone and estrogen can modulate pain perception, the changes detected in vaginal fluid could also contribute to mechanical allodynia in vestibule and vaginal muscles. The progestin, 5 alpha-pregnan3beta, 20 beta diol, was lower in PVD vaginal fluid and is a neurosteroid capable of binding steroid membrane GABA A receptors with inhibitory, excitatory and neurotrophic effects. Androgens have broad anti-inflammatory effects on cellular and molecular levels and can regulate the expression of inflammatory cytokines, known to sensitize nociceptors, such as TNF-alpha, interleukin-6, and interleukin-1beta. Taken together, alterations in steroid hormones (as observed in PVD) could directly affect the vaginal mucosa (e.g., resulting vulnerability to irritation and inflammation) and modulate nociception through changes in innervation.
 

aliml

Member
Joined
Apr 17, 2017
Messages
692
You're welcome @Tansia, I hope you find it useful!


A role for bradykinin signaling in chronic vulvar pain​

Chronic vulvar pain is alarmingly common in women of reproductive age and is often accompanied by psychological distress, sexual dysfunction, and a significant reduction in quality of life. Localized provoked vulvodynia (LPV) is associated with intense vulvar pain concentrated in the vulvar vestibule (area surrounding vaginal opening). To date, the origins of vulvodynia are poorly understood, and treatment for LPV manages pain symptoms, but does not resolve the root causes of disease. Until recently, no definitive disease mechanisms had been identified; our work indicates LPV has inflammatory origins, although additional studies are needed to understand LPV pain. Bradykinin signaling is one of the most potent inducers of inflammatory pain and is a candidate contributor to LPV. We report that bradykinin receptors are expressed at elevated levels in LPV patient versus healthy control vestibular fibroblasts, and patient vestibular fibroblasts produce elevated levels of proinflammatory mediators with bradykinin stimulation. Inhibiting expression of one or both bradykinin receptors significantly reduces proinflammatory mediator production. Finally, we determined that bradykinin activates NFκB signaling (a major inflammatory pathway), while inhibition of NFκB successfully ablates this response. These data suggest that therapeutic agents targeting bradykinin sensing and/or NFκB may represent new, more specific options for LPV therapy.

NF-κB Activators​

NF-κB Inhibitors​

Foods​

Hormones​

Supplements​


A lectin-free diet may also help! A few specific genetic variations have been associated with vulvodynia, including women with vulvodynia being more likely to express the variant allele of mannose-binding lectin (MBL2 gene).


Bromelain (other proteolytic enzymes such as serrapeptase) also has bradykinin-degrading activity. Bromelain hydrolyzes bradykinin and reduces kininogen and bradykinin levels in serum and tissues, improving inflammation.

 
Last edited:
OP
T

Tansia

Member
Joined
Jan 14, 2020
Messages
163
This is all extremly useful information @aliml! I've been taking high dose serrapeptase for the past few months and it did not do anything. I have not yet tried lectin-free diet. Will look into that! The NF-κB Activators and Inibitors - some of them looks surprising like estradiol to be an inhibitor? Anyhow very comprehensive list! Thanks again :)
 
EMF Mitigation - Flush Niacin - Big 5 Minerals

Similar threads

Back
Top Bottom